Stockreport

Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination wi [Read more]